VDA-1102 is an anti-neoplastic agent that utilizes a novel mechanism of action involving selective modulation of VDAC/HK2, a molecular system that is unique to glycolysis and mitochondrial function in cancer cells. VDA-1102’s mechanism of action selectively triggers apoptosis in cancer cells with minimal effects on surrounding normal cells. This selectivity would potentially allow VDA-1102 to be highly efficacious against selected solid tumors while also being well-tolerated.
VDA-1102 has demonstrated significant anti-neoplastic potency in vitro against a range of solid tumors. Therefore, VDA-1102 is being developed in an intravenous formulation as a systemic treatment for solid tumors, such as head & neck and lung cancers.